rsoDeoxyCholic Acid (UDCA) as neuroprotective treatment adjuvant to rhegmatogenous retinal detachment surgery - 2021_0025

Hospital Foch0 个研究点目标入组 120 人开始时间: 2023年11月15日最近更新: 2024年7月22日

适应症

试验速览

暂无简介。

•Patient aged 18 or over, scheduled for vitrectomy surgery, Aphake or pseudophake patients,, With rhegmatogenous retinal detachment affecting 2 or more quadrants,, With rhegmatogenous retinal detachment affecting 2 or more quadrants,, Having signed a consent form,, Affiliated with a health insurance

•Patients who have previously undergone vitrectomy for retinal detachment,, Patients suffering from Crohn's disease, haemorrhagic rectocolitis or other intestinal diseases which may alter the enterohepatic circulation of bile acids, Patients undergoing oral treatment with cholestyramine, colestipol, antacids containing aluminium or magnesium hydroxide and/or smectite (aluminium oxide), ciclosporin, ciprofloxacin, nitrendipine or dapsone, Patients with galactose intolerance, Lapp lactate deficiency or glucose-galactose malabsorption syndrome (rare hereditary diseases), Patient taking part in or being excluded from interventional research and taking medicines prohibited in the context of this study, Patient placed under protective supervision, Patient with vitreous bleeding or any other associated retinal pathology, Monophthalmic patient, Women of childbearing age without an effective method of contraception, Pregnant or breast-feeding woman,, Hypersensitivity to the active substance, to bile acids or to one of the excipients of Ursolvan®, Patients suffering from peptic ulcer, acute or chronic liver disease, acute infection or inflammation of the gall bladder or bile ducts, repeated biliary colic, occlusion of the bile ducts (bile duct or cystic duct occlusion), Patients with radiopaque calcified gallstones, Patient with severe pancreatic disease

发起方

Hospital Foch